Phase 2 Study Shows Rozanolixizumab Is Safe and Effective in Alleviating MG Symptoms
Investigational antibody rozanolixizumab (UCB7665) has proven safe and effective in treating symptoms associated with myasthenia gravis (MG), Phase 2 results show. Based on the results of the MG0002 Phase 2 study (NCT03052751), biopharmaceutical company UCB plans to accelerate the development of rozanolixizumab with a confirmatory study…